Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Pharma
Axsome will begin trial this year in MDD with daytime sleepiness
After reporting a successful trial of Sunosi in patients with ADHD, Axsome has unveiled mixed results for Sunosi in a study in patients with MDD.
Kevin Dunleavy
Apr 1, 2025 4:40pm
MS meds send CNS market toward strongest growth in years
Mar 26, 2025 10:48am
Axsome's Sunosi scores in phase 3 ADHD trial
Mar 25, 2025 11:46am
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
Teva looks to peel back the onion on mental health: exec
Dec 31, 2024 8:00am
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
